文献速递类风湿关节炎脊柱关节炎

类风湿关节炎或中轴型脊柱关节炎患者减量或停用生物/靶向合成改善病情抗风湿药后复发风险的系统综述与荟萃分析

Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该系统综述与荟萃分析纳入22项随机对照试验,评估炎症性关节炎持续缓解或低疾病活动度患者减量或停用b/tsDMARDs与继续标准剂量相比的复发风险。结果显示b/tsDMARD减量较继续治疗复发风险升高(RR 1.45,95%CI 1.19-1.77),TNFi停药复发风险显著升高(RR 2.28,95%CI 1.78-2.93)且持续复发风险升高(POR 3.41,95%CI 1.91-6.09)。结论认为减量似乎是更有利的策略。

要点

  • b/tsDMARD减量较继续治疗复发风险升高(RR 1.45,95%CI 1.19-1.77)。
  • TNFi停药较继续治疗复发风险显著升高(RR 2.28,95%CI 1.78-2.93)。
  • TNFi停药持续复发风险升高(POR 3.41,95%CI 1.91-6.09)。

核心结论

  • TNFi停药复发和持续复发风险高,b/tsDMARD减量复发风险升高但持续复发风险未明确,减量似乎是更有利的策略。

研究设计与样本

  • 在Cochrane Library、PubMed、Embase和Web of Science检索文献。
  • 纳入比较b/tsDMARDs减量和/或停药与标准剂量的随机对照试验,共22项试验:11项评估减量,7项评估停药,4项两者均评估。
  • 仅纳入RA或axSpA人群的试验,采用随机效应荟萃分析,计算风险比(RR)或Peto比值比(POR)及95%CI。

主要发现

  • b/tsDMARD减量较继续治疗复发风险升高(RR 1.45,95%CI 1.19-1.77,I²=42.5%)。
  • b/tsDMARD减量持续复发风险可能升高(POR 1.56,95%CI 0.97-2.52,I²=0%)。
  • TNFi停药较继续治疗复发风险显著升高(RR 2.28,95%CI 1.78-2.93,I²=78%)。
  • TNFi停药持续复发风险升高(POR 3.41,95%CI 1.91-6.09,I²=49%)。
  • RA与axSpA之间复发风险未见明显差异。

局限性

  • b/tsDMARD减量持续复发风险的POR 95%CI为0.97-2.52,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate flare risk when tapering or withdrawing biologic or targeted synthetic DMARDs (bDMARDs or tsDMARDs) compared with continuation in patients with inflammatory arthritis in sustained remission or with low disease activity. METHODS: Articles were identified in the Cochrane Library, PubMed, Embase and Web of Science. Eligible trials were randomized controlled trials comparing tapering and/or withdrawal of bDMARDs and/or tsDMARDs with the standard dose in inflammatory arthritis. Random effects meta-analysis was performed with risk ratio (RR) or Peto's odds ratio (POR) for sparse events and 95% CI. RESULTS: The meta-analysis comprised 22 trials: 11 assessed tapering and 7 addressed withdrawal (4 assessed both). Only trials with an RA or axial SpA (axSpA) population were identified. An increased flare risk was demonstrated when b-/tsDMARD tapering was compared with continuation [RR 1.45 (95% CI 1.19, 1.77), I2 = 42.5%] and potentially increased for persistent flare [POR 1.56 (95% CI 0.97, 2.52), I2 = 0%]. Comparing TNF inhibitor (TNFi) withdrawal with continuation, a highly increased flare risk [RR 2.28 (95% CI 1.78, 2.93), I2 = 78%] and increased odds of persistent flare [POR 3.41 (95% CI 1.91, 6.09), I2 = 49%] were observed. No clear difference in flare risk between RA or axSpA was observed. CONCLUSION: A high risk for flare and persistent flare was demonstrated for TNFi withdrawal, whereas an increased risk for flare but not for persistent flare was observed for b-/tsDMARD tapering. Thus tapering seems to be the more favourable approach. REGISTRATION: PROSPERO (CRD42019136905).

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Uhrenholt L, Christensen R, Dinesen WKH, et al. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2022. PMID: 34864896. doi:10.1093/rheumatology/keab902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。